Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Cherrystone Angel Group
AddedFeb 17, 2024
UpdatedJun 28, 2026
Cherrystone Angel Group

Cherrystone Angel Group

Operating

Cherrystone Angel Group, LLC: A US-based venture capital firm investing in manufacturing, tech, and service sectors.

Location
Providence, RI, US
Founded
2004
Firm
Compare
Portfolio
Employees
Website

Investments

Jaia Robotics
Jaia Robotics

Total Raised

$1M

Rounds

2

Seed$1MJune 2022
Advanced Silicon Group
Advanced Silicon Group

Total Raised

$2.1M

Rounds

4

Seed$1MMay 2021
Lenoss Medical
Lenoss Medical

Total Raised

$1.3M

Rounds

2

Seed$1.3MMarch 2021
Amsel Medical
Amsel Medical

Total Raised

$9.8M

Rounds

4

Convertible Note$1.4MJanuary 2021
Kalion
Kalion

Total Raised

$6.1M

Rounds

9

Series A$350kMarch 2017
Series A$350kMarch 2015
Seed$300kJanuary 2014
KnipBio
KnipBio

Total Raised

$5.3M

Rounds

8

Series B$2MJanuary 2017
Series A$1.6MJanuary 2015
Premama
Premama

Total Raised

$10.4M

Rounds

9

Series BDecember 2016
Convertible NoteMarch 2016
Series A$1.4MOctober 2015
InfoBionic
InfoBionic

Total Raised

$151.4M

Rounds

12

Convertible NoteOctober 2016
Series B$17MApril 2014
Convertible Note$1.2MNovember 2013
Akston Biosciences
Akston Biosciences

Total Raised

$46.6M

Rounds

13

Series C$3.4MAugust 2016
Windgap Medical
Windgap Medical
Public

Total Raised

$42M

Rounds

14

Convertible NoteJuly 2016
Series A$4.2MAugust 2015
Seed$1.5MApril 2014
Concentric
Concentric

Total Raised

$12.4M

Rounds

3

Series A$4.7MJuly 2016
BoardOnTrack
BoardOnTrack

Total Raised

$1.9M

Rounds

4

Convertible NoteFebruary 2016
Seed$1.7MJune 2015
Respiratory Motion
Respiratory Motion
Series D

Total Raised

$33.5M

Rounds

15

Series C$6.5MMarch 2015
Avaxia Biologics
Avaxia Biologics
Debt

Total Raised

$35.3M

Rounds

12

DebtDecember 2014
DebtApril 2014